NCT03314727

Brief Summary

Diets containing excessive salt (\>12 g/day) have negative effects on kidney and cardiovascular system. Considering this known fact, the investigators aimed to study if the amount of the water taken with excessive salt had any part on these negative effects by testing the blood pressure, serum osmolality, endothelial functions, cardiac function, inflammatory parameters and sympathetic nervous system. Excessive dietary salt raises the serum osmolality, which triggers the protection mechanisms of the body. The first mechanism is the secretion of vasopressin from posterior pituitary and the second one is the polyol mediated aldose reductase enzyme activation in renal tubules. In the beginning, water and a little amount of salt is reabsorbed from the kidneys for keeping the serum osmolality in normal ranges by the elevation of vasopressin. Besides the high levels of vasopressin for long durations may have a role in both developments of hypertension and the progression/development of chronic kidney disease. Polyol mediated aldose reductase enzyme turns glucose into sorbitol, which is turned to fructose by sorbitol dehydrogenase activity. Fructose is degraded by fructokinase activity into toxic substances. With this pathway, the acute energy need is satisfied, yet uric acid, local oxidative stress, and inflammatory mediators rise while nitric oxide levels decreasing. These facts are independent risk factors for both kidney disease progression and hypertension. In addition, excessive salt intake may elevate the transforming growth factor beta-1 (TGF-B1) levels, which activates the sympathetic system, inflammation, and endothelial dysfunction. According to these data, the investigators speculate that if they increase the amount of water intake while eating the high salt diet they may decrease the toxic effect of salt with less increase in serum osmolarity. To test this hypothesis, by regulating the salt and water amount in healthy people's diets, the investigators aimed to evaluate the following these parameters; biochemical parameters that could affect the blood and urine osmolality, blood pressure, vascular endothelial functions with the non-invasive flow-mediated dilatation technique and arterial stiffness, systolic and diastolic functions of the heart by transthoracic echocardiography. In addition, it was planned to evaluate the hormonal effects of arginine vasopressin, a long peptide with 39 amino acids, which is longer and easier to measure than vasopressin levels in serum by measuring the pituitary hormone-derived copeptin. Although, decreasing the salt intake is the first step of the treatment in hypertension, and kidney diseases, the compliance rate to less sodium intake is very low (\<20%). The investigators aim is to evaluate the effects of water, which is taken acutely with the excessive salt intake on cardiovascular system and kidney. The findings of the study will important for public health. If the investigators prove their hypothesis, they may recommend increasing high water intake before feeling thirst of which may contribute to decreasing the prevalence of hypertension and kidney disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable hypertension

Timeline
Completed

Started Sep 2017

Shorter than P25 for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2017

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

September 28, 2017

Completed
21 days until next milestone

First Posted

Study publicly available on registry

October 19, 2017

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2017

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2017

Completed
Last Updated

February 9, 2018

Status Verified

September 1, 2017

Enrollment Period

2 months

First QC Date

September 28, 2017

Last Update Submit

February 8, 2018

Conditions

Keywords

Osmolar ConcentrationOxidative StressSaltInflammationEndothelial FunctionHypertension

Outcome Measures

Primary Outcomes (1)

  • Change from baseline systolic and diastolic blood pressure

    Systolic and diastolic blood pressures are measured with an aneroid sphygmomanometer. Unit of measurement is mmHg.

    Baseline time 0, Hour 1, Hour 2, Hour 3, Hour 4

Secondary Outcomes (5)

  • Serum osmolarity increase

    Baseline time 0, Hour 1, Hour 2, Hour 3, Hour 4

  • Change from baseline blood copeptin levels

    Baseline time 0, Hour 1, Hour 2, Hour 3, Hour 4

  • Change from baseline augmentation index

    Baseline time 0, Hour 4

  • Change from baseline pulse wave velocity

    Baseline time 0, Hour 4

  • Change from baseline flow mediated dilation

    Baseline time 0, Hour 4

Study Arms (2)

Control group

NO INTERVENTION

Drink 200 ml soup with no added salt

High salt (NaCl) intake

EXPERIMENTAL

Group 2: Drink 200 ml soup with 3 g added salt Group 3: Drink 200 ml soup with 3 g added salt plus 500 ml water Group 4: Drink 200 ml soup with 3 g added salt plus 750 ml water

Other: High salt (NaCl) intake

Interventions

Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels

High salt (NaCl) intake

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy, no smoker, no obese \>30 BMI, no drug use in the previous month

You may not qualify if:

  • Any systemic disease, no past history of any cardiovascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Koc University Hospital

Istanbul, 34010, Turkey (Türkiye)

Location

MeSH Terms

Conditions

HypertensionHypernatremiaInflammation

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesWater-Electrolyte ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mehmet Kanbay, MD

    Koc University Sch. Med. Dept. Internal Med. Nephrology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 28, 2017

First Posted

October 19, 2017

Study Start

September 1, 2017

Primary Completion

November 1, 2017

Study Completion

November 30, 2017

Last Updated

February 9, 2018

Record last verified: 2017-09

Locations